A Plerixafor-Based Strategy Allows Adequate Hematopoietic Stem Cell Collection in Poor Mobilizers: Results from the Canadian Special Access Program  by Sheppard, Dawn et al.
Abstracts / Biol Blood Marrow Transplant 20 (2014) S104eS127S118quintile was associated with a 40% decrease in the risk of
engraftment failure (OR 0.60, 95% CI 0.41-0.87). Even when
adjusted for cell dose infused, a higher # of collected CD34+
cells was associated with decreased time to platelet
engraftment (HR1.15, CI 1.00-1.32, p¼.052), but not ANC
engraftment (HR 1.07, p¼.35). Positive blood cultures within
30 days of ASCT were associated with engraftment failure
(p¼.0035), while race, sex, # of collections for the trans-
planted dose and mobilization regimen did not appear to
affect engraftment. We also observed that prior Imid use
demonstrated a trend toward less engraftment failure (OR
0.41, 95%CI 0.17-1.01; p¼.052).
Although a moderate correlation was observed between
the variables CD34 cells collected and CD34 cells infused, a
sensitivity analysis by omitting either variable did not iden-
tify a signiﬁcantly different estimates.153
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Background: The collection of a minimum number of he-
matopoietic stem cells (HSC), generally deﬁned as 2 x 106
CD34+ cells/kg, is a prerequisite for proceeding to HSCT.
Primary mobilization failure occurs in 5 e 40% of patients.1-5
When used to unselected patients undergoing a ﬁrst mobi-
lization attempt, plerixafor plus GCSF allows more CD34+
cells to be mobilization with fewer aphereses than GCSF
alone.6, 7 There are no publications describing the patterns of
plerixafor use at Canadian transplant centres, nor is there
data to guide determinations of cost-effectiveness of mobi-
lization using plerixafor from the Canadian perspective.
Methods: The objectives of this study were to: 1) Summa-
rize the published studies of plerixafor-based mobilization
during compassionate access programs, and 2) Describe the
Canadian experience with plerixafor during its availability
though Health Canada’s Special Access Program (SAP). A
literature search was performed and studies were grouped
into three strategies: upfront, preemptive and salvage. In
Canada, plerixafor was available through the SAP, and fun-
ded by Genzyme/Sanoﬁ from September 2008 to December
2010.
Results: Thirteen articles were identiﬁed. In all but one
study, plerixafor was used as part of a preemptive and/or
salvage strategy. The proportion lf patients in whom a min-
imum of 2 x 106 CD34+ cells/kg was collected ranged from 37
e 100%. At the time of publication, 17 e 87% of patients had
proceeded to transplantation.
Thirteen Canadian centres provided data on a total of 132
patients, the majority of whom had multiple myeloma or
lymphoma, and had undergone a median of 1 prior mobili-
zation attempt (range 0 e 3). Plerixafor was used preemp-
tively in 23 (17%) patients and as salvage in 109 (83%)
patients. In 96 (73%) patients, therewas successful collection.
Of the 23 patients in whom plerixafor was used preemp-
tively, 19 (83%) had successful collections. Of the 109 patients
in whom the drug was used as part of a salvage strategy,
77 (71%) had successful collections. Of the entire cohort,
99 (75%) of patients went on to receive an autologous
transplant.Discussion: Our study summarizes the published experience
with plerixafor-based mobilization during compassionate
drug access programs and describes the Canadian experience
when plerixafor was freely available through Health Cana-
da’s SAP. Canadian practice was similar to published inter-
national experience.
Plerixafor use decreased signiﬁcantly when it was no
longer freely available. This may be a reﬂection of limited
resources, a lack of belief in the preemptive use of plerixafor
or knowledge of the most cost-effective way to use it. The
pharmacoeconomics of mobilization likely vary from centre
to centre and are affected by multiple factors such as the
patient population, infrastructure, available resources, and
who is paying for plerixafor.154
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Background: Collection of a minimum number of hemato-
poietic progenitor cells (HPC), usually deﬁned as 2 x 106
CD34+ cells/kg, is required to ensure timely neutrophil and
platelet recovery.1-4 The majority of centres use peripheral
blood-mobilized HPCs as the source of progenitor cells for
autologous transplantation,5 but the method used to predict
the ﬁnal apheresis product CD34+ cell content, and thus the
whole blood volume to process during apheresis collection,
has not been standardized. In the mid-1990s, Mitterer et al.
demonstrated on a 28-patient cohort that the correlation
between the pre-apheresis peripheral blood CD34+ cell
count and the number of CD34+ cells/kg collected could be
used to determine the blood volume to process during
apheresis to harvest the desired number of CD34+ cells/kg
(target-value tailored, TVT, collection). Using this concept
and local data, the Ottawa Canadian Blood Services Stem Cell
Laboratory created a similar regression model to help
determine the blood volume to process during apheresis
collection.
Methods: We conducted a retrospective study of all pe-
ripheral blood HPC apheresis collections performed at the
Ottawa Hospital from January 1, 2003 to December 31, 2011.
Our objective was to validate the TVT approach, as modiﬁed
by our institution.
Results: From 2003 to 2011, there were 815 peripheral blood
HPC collections by apheresis. The majority, 696 (85.4%), were
autologous collections and 119 (14.6%) were allogeneic do-
nors. The most common diagnoses were multiple myeloma
and aggressive non-Hodgkin lymphoma (NHL). The median
age of the cohort was 51.1 (range 14.3 e 70.4) years. The
median number of prior chemotherapy regimens was 1
(range 0 e 5). The majority of collections, 635 (93.7%), were
ﬁrst attempts.
The median pre-collection peripheral blood CD34+ cell
count was 2.23 (interquartile range, IQR 1.07 e 5)/mL. The
